Literature DB >> 3023314

Limited autolysis of calcium-activated neutral protease (CANP): reduction of the Ca2+-requirement is due to the NH2-terminal processing of the large subunit.

S Imajoh, H Kawasaki, K Suzuki.   

Abstract

Calcium-activated neutral protease (rabbit mCANP), composed of large and small subunits, was converted to a lower-Ca2+-requiring form (derived microCANP) by limited autolysis in the presence of Ca2+. The NH2-terminal regions of the two subunits of mCANP were cleaved by autolysis, but the COOH-termini remained intact after autolysis. When native mCANP or derived microCANP was dissociated into subunits, the proteolytic activity of the large subunit was reduced to 2-5% of that of the native dimeric enzyme. The Ca2+-sensitivity of one hybrid CANP reconstituted from the large subunit of derived microCANP and the small subunit of native mCANP was similar to that of derived microCANP. However, the other hybrid molecule composed of the large subunit of native mCANP and the small subunit of derived microCANP required a high concentration of Ca2+ for activity, like native mCANP. These results indicate that the Ca2+-sensitivity of derived microCANP is determined by the structural change of the large subunit resulting from loss of its NH2-terminal region. The autolysis of the small subunit apparently has no effect on the reduction of the Ca2+-requirement.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023314     DOI: 10.1093/oxfordjournals.jbchem.a121755

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

1.  Investigation of the structural basis of the interaction of calpain II with phospholipid and with carbohydrate.

Authors:  C Crawford; N R Brown; A C Willis
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

2.  Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse.

Authors:  James G Tidball; Melissa J Spencer
Journal:  J Physiol       Date:  2002-12-15       Impact factor: 5.182

3.  Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system.

Authors:  S L Meyer; D Bozyczko-Coyne; S K Mallya; C M Spais; R Bihovsky; J K Kaywooya; D M Lang; R W Scott; R Siman
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

4.  The effects of truncations of the small subunit on m-calpain activity and heterodimer formation.

Authors:  J S Elce; P L Davies; C Hegadorn; D H Maurice; J S Arthur
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

5.  The effects of autolysis on the structure of chicken calpain II.

Authors:  C Crawford; A C Willis; J Gagnon
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

6.  Autoantibodies directed against the protease inhibitor calpastatin in psoriasis.

Authors:  Y Matsushita; Y Shimada; S Kawara; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 7.  The calpain system and cancer.

Authors:  Sarah J Storr; Neil O Carragher; Margaret C Frame; Tim Parr; Stewart G Martin
Journal:  Nat Rev Cancer       Date:  2011-05       Impact factor: 60.716

8.  Studies of the active site of m-calpain and the interaction with calpastatin.

Authors:  C Crawford; N R Brown; A C Willis
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

9.  Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases.

Authors:  T Mimori; K Suganuma; Y Tanami; T Nojima; M Matsumura; T Fujii; T Yoshizawa; K Suzuki; M Akizuki
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

10.  Calpains promote α2β1 integrin turnover in nonrecycling integrin pathway.

Authors:  Nina Rintanen; Mikko Karjalainen; Jonna Alanko; Lassi Paavolainen; Anita Mäki; Liisa Nissinen; Moona Lehkonen; Katri Kallio; R Holland Cheng; Paula Upla; Johanna Ivaska; Varpu Marjomäki
Journal:  Mol Biol Cell       Date:  2011-12-07       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.